Drug details

Zevalin (ibritumomab tiuxetan)

type of Antineoplastics, Anti-CD20 Monoclonal Antibodies

Zevalin (ibritumomab tiuxetan) is a protein that targets white blood cells in the body used in combination with other medicines to treat non-Hodgkin's lymphoma.

This drug may have the following side effects:
  • hives,
  • difficulty breathing,
  • swelling of your face, lips, tongue, or throat,
  • fever,
  • easy bruising,
  • unusual bleeding,
  • pale skin,
  • lightheadedness,
  • shortness of breath,
  • cold hands and feet,
  • tiredness,
  • weakness,
  • sore throat,
  • burning eyes,
  • skin pain,
  • red or purple skin rash with blistering and peeling,
  • mouth sores,
  • skin sores,
  • unusual weakness,
  • purple or red spots under your skin,
  • cough, and
  • chest tightness or pain spreading to your jaw or shoulder,
  • redness, ulcers, or skin changes where the medicine was injected,
  • skin rash (may occur during treatment or several months after)
The following drugs are related to Zevalin, either as a replacement or used together:
  • Anthim (obiltoxaximab intravenous infusion)
  • Beleodaq (belinostat for injection for intravenous use)
  • Bexxar (tositumomab and iodine 1131 tositumomab)
  • Breyanzi (lisocabtagene maraleucel suspension for intravenous infusion)
  • Vyxeos (daunorubicin and cytarabine for injection)
  • Decadron (dexamethasone)
  • Idhifa (enasidenib tablets)
  • Octreoscan (indium in -111 pentetreotide kit for intravenous use)
  • Jeanatope 1-125 (iodinated 1-125 albumin injection)
  • Riabni (rituximab-arrx injection)
  • Zolinza (vorinostat)
The following supplements are related to Zevalin, and may be used together with the drug:
  • Melatonin (s.)
  • Adenosine (s.)
  • Coriolus Mushroom (s.)